The Interferon Beta pipeline drugs market research report outlays comprehensive information on the Interferon Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interferon Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Musculoskeletal Disorders, and Respiratory which include the indications Non-Small Cell Lung Cancer, Metastatic Melanoma, Systemic Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus (SCLE), Osteoarthritis, Polymyositis, and Idiopathic Pulmonary Fibrosis. It also reviews key players involved in Interferon Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Interferon Beta pipeline targets constitutes close to eight molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 2, and 3 respectively. Similarly, the universities portfolio in Phase I comprises 1 molecule.
Interferon Beta overview
Interferon Beta is a protein that in humans is encoded by a gene IFNB1. It belongs to interferon family of signaling proteins, which are released as part of the innate immune response to pathogens. These are also involved in cell differentiation and anti-tumor defenses and overactivation of type I interferon secretion is linked to autoimmune diseases.
For a complete picture of Interferon Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
